Lumora’s patented Sample Preparation technologies in Commercial Use 


Cambridgeshire, UK, 16 March 2015 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, today announces that one of its proprietary sample preparation technologies, Heat Elution, has been selected for use by a number of US Government Departments.

Lumora’s novel sample preparation technology, Heat Elution, will be used to improve sample extraction from a range of pathogenic and non-pathogenic samples within various government research programs and laboratories 

Lumora’s Heat Elution sample preparation technology has a number of advantages over other commercial sample preparation technologies including; speed, ease of use, nucleic acid quality and yield. Lumora has a developed a range of applications for the Heat Elution technology spear headed in the clinical area by its FFPE column which shows enhancement recovery and quality of extraction over  other technologies for this critical and sometimes technically challenging sample type. 

The company’s sample preparation technologies can be used for the extraction of DNA and RNA, making them ideal for molecular diagnostics and NGS across a range of sectors including clinical, food and veterinary. The applications for Lumora’s tests include human health, the food safety, and veterinary markets. 

Laurence Tisi, CEO of Lumora, said: “This early commercial adoption of our sample preparation technology is a major step for Lumora; it is further important validation of the effectiveness of our sample preparation technologies and a validation of the novel approaches we are bringing to the molecular diagnostics and NGS sectors.” 

Hayden Jeffreys, Commercial Director at Lumora, added: “With the strength of our technology illustrated through its adoption by a major set of users we now expect to see further commercial traction and broad interest in our technologies. We already have a significant number of deals and partnerships in place, but we now expect to see this increase as the capabilities of our sample preparation technologies become more widely adopted.” 


For further information please contact:

Tony Stephenson, Director

Exitus Communications 

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  


Notes to Editors: 


About Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in commercialising its technology and our development and commercialisation partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.